Stock Comparison

BRKR vs LLY

Bruker Corp vs Eli Lilly and Co

The Verdict

Dead heat. Both scored 0.5/10.

BRKR

Bruker Corp

0.5

out of 10

Distressed

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$5.1B

Market Cap

$965.0B

-222.2

P/E Ratio

52.6

-0.3%

Profit Margin

N/A

13.6%

Return on Equity

N/A

0.8

Debt-to-Equity

N/A

Moderate

Overall Risk

Moderate

0.5

DVR Score

0.5

The Deep Dive

BRKR0.5/10

Bruker Corp. remains a high-quality, innovative leader in specialized scientific instruments with a strong competitive moat, primarily in areas like NMR and Mass Spectrometry. Its financial health, including a healthy balance sheet (current ratio 1.73, D/E 0.75) and positive Q4 FCF ($207M), suggests stability. However, Q4 2025 results showed flat revenue (-0.2% YoY), a significant 5.1% organic dec...

Full BRKR Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.